AstraZeneca says EU approves Trixeo triple-inhaler for asthma maintenance treatment
AZN•EU approves Trixeo Aerosphere for asthma maintenance
AstraZeneca says the EU has cleared Trixeo Aerosphere as a maintenance asthma therapy in patients aged 12 and older who remain uncontrolled on medium-dose ICS/LABA.
The single-inhaler triple combination adds a LAMA to ICS/LABA; it is marketed as Breztri Aerosphere in the US, China and Japan.
The approval was backed by Phase III KALOS and LOGOS data showing better lung function and lower severe exacerbation rates versus ICS/LABA.
